Iowa School for the Deaf

CEO Charlie Funk to Retire From MidWestOne In 2022

Retrieved on: 
Monday, February 7, 2022
Board of directors, GLOBE, Culture, Spencer Stuart, MidWestOne Financial Group, Time, Board, Funk, Company, Director, Trust, Family, CEO, IOWA, Georgetown University, Bank, Iowa School for the Deaf, Nasdaq, Management

IOWA CITY, Iowa, Feb. 07, 2022 (GLOBE NEWSWIRE) -- MidWestOne Financial Group, Inc. (Nasdaq: MOFG), parent company of MidWestOne Bank, today announced that its Chief Executive Officer (CEO) Charlie Funk, 67, will retire later this year, following a successful 21-year career with the organization.

Key Points: 
  • IOWA CITY, Iowa, Feb. 07, 2022 (GLOBE NEWSWIRE) -- MidWestOne Financial Group, Inc. (Nasdaq: MOFG), parent company of MidWestOne Bank, today announced that its Chief Executive Officer (CEO) Charlie Funk, 67, will retire later this year, following a successful 21-year career with the organization.
  • Funk joined MidWestOne in November 2000 and has served as CEO since March 2008.
  • Funk will remain with MidWestOne until a successor is chosen and in place to ensure a seamless transition.
  • MidWestOne is the parent company of MidWestOne Bank, which operates banking offices in Iowa, Minnesota, Wisconsin, Florida, and Colorado.

Foresight Diagnostics Establishes Scientific Advisory Board with Appointment of Sandra Horning, M.D.

Retrieved on: 
Wednesday, January 19, 2022
Coronavirus Scientific Advisory Board (Turkey), Woman, Patient, MRD, Technology, Stanford University, Blood, Journal of Clinical Oncology, LinkedIn, Publication, Journal, University, The American Journal of Medicine, Clinical Cancer Research, Internal medicine, Leukemia, Lymphoma, Gilead Sciences, GLOBE, Society, American Journal, Health, Health care, Cancer, DNA, The Washington Campus Board of Directors, American Society of Clinical Oncology, Industry, B-cell lymphoma, Liquid biopsy, FACP, Annals of Internal Medicine, Hematopoietic stem cell transplantation, Lymphoid leukemia, SAB, Mutation, Iowa School for the Deaf, Twitter, Foresight, Board, Neoplasm, Physician, Medical device, Pharmaceutical industry

AURORA, Colo., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Foresight Diagnostics today announced the appointment of Sandra Horning, M.D., FACP, FASCO, to its newly established Scientific Advisory Board (SAB).

Key Points: 
  • AURORA, Colo., Jan. 19, 2022 (GLOBE NEWSWIRE) -- Foresight Diagnostics today announced the appointment of Sandra Horning, M.D., FACP, FASCO, to its newly established Scientific Advisory Board (SAB).
  • Sandra has been at the forefront of biopharmaceutical innovation for many years, and brings significant experience and insight to our team, said Jake Chabon, Ph.D., co-founder and Chief Executive Officer of Foresight Diagnostics.
  • We look forward to Sandras contributions to Foresight as we realize our vision for improved patient care.
  • Dr. Horning is a co-founder and board member of EQRx and currently serves on the Boards of Directors at Gilead Sciences, Moderna and Olema Oncology.